Clinical trial
The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias
NCT00472433 · Phramongkutklao College of Medicine and Hospital, Other · Terminated
Key facts
| NCT number | NCT00472433 |
|---|---|
| Title | The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias |
| Official title | A Phase II Study of Alemtuzumab in Autoimmune Cytopenias |
| Lead sponsor | Phramongkutklao College of Medicine and Hospital, Other |
| Collaborators | Bayer Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Autoimmune Cytopenias |
| Intervention type | Drug |
| Interventions | Alemtuzumab |
| Enrollment | 30 |
| Start date | Mar 1, 2007 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2009 |
| First posted | May 11, 2007 |
| Last update posted | Jun 22, 2009 |
| Countries | Thailand |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: